OMNARIS® (ciclesonide) Nasal Allergy Spray: Terms of Use

Omnaris(R) (ciclesonide) Nasal Spray, 50 mcg

Sign Up for Updates

Terms of Use

NO WARRANTY
Information accessed through this web site is presented in summary and interactive form and is not exhaustive. Sunovion Inc. and its U.S. subsidiaries and affiliates make no warranties or representations as to its accuracy or completeness. This information is provided "as is" without warranty of any kind, either express or implied, including but not limited to implied warranties of merchantability, fitness for particular purpose, or non-infringement. Some jurisdictions do not allow exclusion of implied warranties so the above exclusion may not apply to you. Certain links on this site lead to sites or sources located on servers maintained by third parties over which Sunovion has no control. Sunovion makes no representation as to the accuracy or any other aspect of the information contained in or on such sites, sources or servers, nor does Sunovion necessarily endorse such sites or sources. Neither Sunovion nor its affiliates or their respective employees shall be liable in any way for any legal claims, whether in contract, tort or otherwise in any way connected with the use or performance of this web site or any information linked or referenced by this site or any other information or Internet site which link to this site.

The information included in (or accessible from) this web site may contain forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy, potential benefits, and successful development of the Sunovion's pharmaceuticals under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the submission, acceptance, and approval of regulatory filings; the results of clinical trials with respect to products under development; the scope of the Sunovion's patent protection with respect to such product candidates; the commercial success of Sunovion's products; the ability of the company to attract and retain qualified personnel; the performance of Sunovion's licensees; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in any periodic reports filed with the Securities and Exchange Commission.

NON-COMMERCIAL USE
Sunovion gives you permission to copy pages of www.sunovionmeetings.com documents published herein on the Internet for non-commercial use only, provided any copy of these documents that you make shall retain all copyright and other proprietary notices and any disclaimers contained herein.

COPYRIGHTS/TRADEMARKS
All images, trademarks and text are the property of Sunovion and may not be downloaded, distributed, sorted, reused, reported, modified or otherwise used except as provided herein, without the express written permission of Sunovion. All product and service names appearing in a typeface different from that of the surrounding text or with a trademark symbol, including the "Sunovion" logo, are trademarks and service marks owned by Sunovion Pharmaceuticals Inc. or its subsidiaries or affiliates or another company. Use of these marks, except as permitted herein, is expressly prohibited. Nothing contained herein shall be construed as conferring, by implication, estoppel or otherwise, any license or right under any patent or trademark of Sunovion or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Sunovion copyright.

NO CONFIDENTIALITY
No confidential relationship shall be established in the event that any user of this Internet site should make any oral, written or electronic response to Sunovion (such as feedback, questions, comments, suggestions, ideas, etc.). Such response and any information submitted therewith shall be considered non-confidential, and Sunovion shall be free to reproduce, publish or otherwise use such information for any purposes whatsoever including, without limitation, the research, development, manufacture, use or sale of products incorporating such information. The sender of any information to Sunovion is fully responsible for its content, including its truthfulness and accuracy and its non-infringement of any other person's proprietary rights.

Sunovion may, at any time, revise these Terms of Use by updating this page. You are bound by any such revisions and should therefore periodically visit this page to review the then current Terms of Use.

Small Font

Medium Font

Large Font

Join the Relief is Here Co-pay Program

Pay Only $17

And pay only $17 every time you fill your prescription.*

Start Saving Now

* Most insured patients will pay no more than $17 monthly with a maximum benefit of $50 per fill. Restrictions apply and co-pay amounts may vary.
See program rules and eligibility

Why OMNARIS^® (ciclesonide) Nasal Spray?

24/7 relief^‡ for all your nasal allergy symptoms

Find out more

^‡ Symptom relief begins within 24-48 hours after the first dose.

Indication and Dosing

OMNARIS^® (ciclesonide) Nasal Spray is for the treatment of nasal allergy symptoms associated with seasonal allergies in adults and children 6 years of age and older, and with year-round allergies in adults and adolescents 12 and older. It is for use in the nose only. OMNARIS is used 1 time each day, 2 sprays per nostril.

Important Safety Information

Do not spray OMNARIS Nasal Spray in your eyes or directly onto your nasal septum (the wall inside your nose between your two nostrils).

OMNARIS Nasal Spray may cause serious side effects, including:

nose bleeds and nasal ulcers. Call your healthcare provider right away if you start to have more nose bleeds or nasal ulcers.
hole in the cartilage in the nose (nasal septal perforation). Stop using OMNARIS Nasal Spray and call your doctor right away if you have symptoms of a nasal perforation. Symptoms of nasal perforation may include: crusting in the nose, nosebleeds, runny nose, and a whistling sound when you breathe.
thrush (Candida), a fungal infection in your nose, mouth, or throat. Tell your healthcare provider if you have any redness or white colored patches in your mouth or throat.
slow wound healing. You should not use OMNARIS Nasal Spray until your nose has healed, if you have a sore in your nose, if you have had surgery in your nose, or if your nose has been injured.
eye problems such as glaucoma and cataracts. If you have a history of glaucoma or cataracts or have a family history of eye problems, you should have regular eye exams while you use OMNARIS Nasal Spray.
immune system problems that may increase your risk of infections. You are more likely to get infections if you take medicines that may weaken your body's ability to fight infections. Avoid contact with people who have contagious diseases such as chicken pox or measles while you use OMNARIS Nasal Spray. Symptoms of an infection may include: fever, pain, aches, chills, feeling tired, nausea, and vomiting.
adrenal insufficiency. Adrenal insufficiency is a condition in which the adrenal glands do not make enough steroid hormones. Call your healthcare provider right away if you experience the following symptoms of adrenal insufficiency: tiredness, weakness, dizziness, nausea, and vomiting.
slowed or delayed growth in children. A child's growth should be checked regularly while using OMNARIS Nasal Spray.
allergic reactions. Call your healthcare provider right away if you experience swelling of the lips, tongue, or throat.

The most common side effects that may occur with OMNARIS Nasal Spray are headache, nosebleed, sore throat and ear pain.

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of OMNARIS Nasal Spray.

For more information, please see the OMNARIS Full Prescribing Information and the OMNARIS Patient Information. You may also call 1-888-394-7377.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.

OMNARIS^® (ciclesonide) Nasal Spray is available by prescription. Ask your healthcare professional if OMNARIS Nasal Spray is right for you.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. This site is intended for U.S. residents 18 years of age and older. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

OMNARIS is the registered trademark of Takeda GmbH, used under license. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd., Sunovion Logo is a registered trademark of Dainippon Sumitomo Pharma Co. Ltd.